Literature DB >> 31042599

PulseRider-Assisted Coil Embolization for Treatment of Intracranial Bifurcation Aneurysms: A Single-Center Case Series with 24-Month Follow-up.

Nobuyuki Sakai1, Hirotoshi Imamura1, Koichi Arimura1, Takayuki Funatsu1, Mikiya Beppu1, Keita Suzuki1, Hiromasa Adachi1, Tomohiro Okuda1, Yuichi Matsui1, Shuhei Kawabata1, Ryo Akiyama1, Kazufumi Horiuchi1, Shoichi Tani1, Hidemitsu Adachi1, Chiaki Sakai1, Naoki Kaneko2, Satoshi Tateshima3.   

Abstract

BACKGROUND: Although endovascular coiling of unruptured aneurysms is widely accepted, the endovascular treatment of wide-neck bifurcation aneurysms remains one of the most challenging morphologies. Our purpose was to describe our experience with 24-month follow-up for the treatment of unruptured intracranial bifurcation aneurysms using the PulseRider (Cerenovus, New Brunswick, NJ).
METHODS: This study is a single-center, single-arm registry performed under institutional review board control to evaluate efficacy and safety of the PulseRider. Patients with bifurcation aneurysms were identified and enrolled prospectively. Angiography immediately after treatment and at 6 months, and magnetic resonance imaging and magnetic resonance angiography at 12- and 24-month follow-up were retrospectively analyzed. A modified Rankin score was obtained prior to procedure, at discharge, and at 6-, 12- and 24-month follow-up visits.
RESULTS: Eight patients with a mean age of 66 years were treated with the PulseRider. All patients had bifurcation aneurysms (2 anterior communicating, 2 carotid terminus, and 4 basilar apex). The aneurysm diameters ranged from 4.6 to 13.6 mm (mean 7.4 mm) with dome/neck ratio ranging from 1.4 to 2.2 (mean 1.6). In all cases, the PulseRider was successfully deployed. Complete occlusion was demonstrated at 6-month follow-up on 6 of 8 (75%), near complete occlusion in 1 of 8 (12.5%), and residual aneurysm in 1 of 8 (12.5%) patients. There was no change or recurrence on magnetic resonance angiography, nor clinical complication after the procedure through 24-month follow-up.
CONCLUSIONS: Our experience with 24-month follow-up demonstrated favorable efficacy in the treatment of intracranial wide-neck bifurcation aneurysms using the PulseRider.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endovascular treatment; Follow-up; Intracranial aneurysm; PulseRider

Year:  2019        PMID: 31042599     DOI: 10.1016/j.wneu.2019.04.177

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

Review 1.  Neurosurgical management of aneurysms of the vertebrobasilar system: increasing indications for endovascular therapy with a continued role for open microneurosurgery.

Authors:  Anthony S Larson; Tapan Mehta; Andrew W Grande
Journal:  Neurosurg Rev       Date:  2021-01-06       Impact factor: 3.042

2.  Long-term follow-up of the pCONus device for the treatment of wide-neck bifurcation aneurysms.

Authors:  Adrien Guenego; Benjamin Mine; Thomas Bonnet; Stephanie Elens; Juan Vazquez Suarez; Lise Jodaitis; Noémie Ligot; Gilles Naeije; Boris Lubicz
Journal:  Interv Neuroradiol       Date:  2021-09-13       Impact factor: 1.764

3.  Efficacy and safety of PulseRider for treatment of wide-necked intracranial aneurysm-A systematic review and meta-analysis.

Authors:  Raymond Pranata; Emir Yonas; Rachel Vania; Prijo Sidipratomo; Julius July
Journal:  Interv Neuroradiol       Date:  2020-07-07       Impact factor: 1.610

4.  Initial Experience with LVIS EVO Stents for the Treatment of Intracranial Aneurysms.

Authors:  Wojciech Poncyljusz; Kinga Kubiak
Journal:  J Clin Med       Date:  2020-12-07       Impact factor: 4.241

5.  Non-contrast-enhanced silent magnetic resonance angiography for assessing cerebral aneurysms after PulseRider treatment.

Authors:  Tomoaki Suzuki; Hitoshi Hasegawa; Kazuhiro Ando; Kohei Shibuya; Haruhiko Takahashi; Shoji Saito; Makoto Oishi; Yukihiko Fujii
Journal:  Jpn J Radiol       Date:  2022-04-17       Impact factor: 2.701

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.